Literature DB >> 30670824

Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation.

Shin-Ichiro Fujiwara1, Junya Kanda2, Raine Tatara3, Hiroyasu Ogawa4, Takahiro Fukuda5, Hirokazu Okumura6, Kazuteru Ohashi7, Koji Iwato8, Yasunori Ueda9, Ken Ishiyama10, Tetsuya Eto11, Ken-Ichi Matsuoka12, Hirohisa Nakamae13, Makoto Onizuka14, Yoshiko Atsuta15, Yoshinobu Kanda16,17.   

Abstract

The significance of low-dose total body irradiation (TBI) in HLA-mismatched reduced-intensity conditioning stem cell transplantation (RICT) remains unknown. We, retrospectively, evaluated the impact of low-dose TBI in patients with hematological malignancies who received first RICT from ≥1 antigen-mismatched donors between 2004 and 2014. Of the 575 patients, 361 patients received low-dose TBI (2 or 4 Gy). There were no significant differences in neutrophil engraftment or platelet recovery between TBI and non-TBI groups. The benefit of low-dose TBI on neutrophil engraftment was not observed in any subgroups. Low-dose TBI was not associated with decreased secondary graft failure. Suppressed mixed chimerism and autologous hematopoiesis by low-dose TBI was observed. There were no significant differences in cumulative incidences of acute GVHD or nonrelapse mortality rates in either group; however, low-dose TBI improved overall survival (OS), especially in patients with high-risk disease, multi-HLA mismatch, and fludarabine/busulfan conditioning. Multivariate analysis demonstrated that low-dose TBI was an independent prognostic factor for OS. Compared with the non-TBI group, 4 Gy TBI, but not 2 Gy TBI, was associated with increased acute GVHD and reduced relapse. These findings suggest that low-dose TBI may be beneficial for patients at high risk for relapse in HLA-mismatched RICT.

Entities:  

Year:  2019        PMID: 30670824     DOI: 10.1038/s41409-019-0434-3

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors.

Authors:  Brian Kornblit; Barry E Storer; Niels S Andersen; Michael B Maris; Thomas R Chauncey; Effie W Petersdorf; Ann E Woolfrey; Mary E D Flowers; Rainer Storb; David G Maloney; Brenda M Sandmaier
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

2.  [Containing total marrow irradiation conditioning regimen for patients with leukemia undergoing hematopoietic stem cell transplantation].

Authors:  X Y Zhao; H F Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.